ArticleBiological procedures online2026
Activation of PPARγ and CPT1A Mediates the Hepatoprotective Effect of Ginsenoside CK against NAFLD in Rats.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonalcoholic fatty liver disease (NAFLD) is a significant underlying driver of hepatocellular carcinoma; however, current clinical treatment options remain limited. Ginsenoside CK (CK), a natural bioactive compound, has shown promise in modulating lipid metabolism and protecting liver function. Nevertheless, its therapeutic potential against the pathogenesis of NAFLD and the associated molecular pathways is not fully understood. This study employed an integrated strategy that combines transcriptomic analysis with both in vivo and in vitro validation, utilizing a high-fat diet (HFD)-induced rat model to elucidate the efficacy and molecular mechanisms of CK in ameliorating NAFLD.
methodsAn NAFLD rat model was established through HFD feeding to assess the effects of CK on various physiological and biochemical parameters, thereby clarifying its role in regulating lipid metabolism and providing hepatoprotection in vivo. Additionally, a free fatty acid (FFA)-induced Huh7 cell model was constructed to evaluate the in vitro activity of CK in promoting lipid metabolism and inhibiting lipid accumulation. Subsequently, transcriptomic analysis was conducted to identify potential targets and elucidate the mechanisms underlying the effects of CK. Finally, the proposed mechanism was verified through in vivo experiments.
resultsIn vivo results indicated that CK treatment significantly mitigated the increases in body weight and organ indices induced by a HFD. Additionally, CK improved biochemical parameters in both liver and serum, alleviated liver injury, steatosis, and insulin resistance, thereby providing a protective effect on liver tissue. Furthermore, CK markedly reduced the deposition of intracellular lipid droplets in hepatocytes. It also enhanced the expression of fatty acid metabolism-related genes, CPT1 and CPT2, in the liver, while downregulating the expression of lipogenic genes, including ACC1, FAS, and SREBP1c. Mechanistic investigations revealed that CK modulates the PPARγ/CPT1A signaling axis, suppresses the expression of hepatic lipogenic genes, reduces lipid accumulation, and consequently improves insulin resistance and liver injury.
conclusionOur study demonstrates that CK attenuates NAFLD progression by regulating the PPARγ/CPT1A signaling axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.